Topics

Clinical Trials About "Treatment targets with advanced prostate cancers" RSS

18:02 EDT 18th July 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Treatment targets with advanced prostate cancers" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Treatment targets with advanced prostate cancers" on BioPortfolio

We have published hundreds of Treatment targets with advanced prostate cancers news stories on BioPortfolio along with dozens of Treatment targets with advanced prostate cancers Clinical Trials and PubMed Articles about Treatment targets with advanced prostate cancers for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Treatment targets with advanced prostate cancers Companies in our database. You can also find out about relevant Treatment targets with advanced prostate cancers Drugs and Medications on this site too.

Showing "Treatment targets with advanced prostate cancers" Clinical Trials 1–25 of 29,000+

Extremely Relevant

AMG 386 and Abiraterone for Advanced Prostate Cancer

Background: - Advanced prostate cancer is treated with surgery or drugs that lower the levels of androgens (male hormones) in the body. However, some cancers become resistant to this treatment. These types of cancers are known as castration-resistant prostate cancers. - Interfering with the growth of blood vessels that feed tumors can slow prostate cancer growth. AMG 386, a new anticancer drug, targets the blood vessels that feed tumors. It has...


Relevant

Study of SU11248 in Men With Advanced Prostate Cancer

- There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments. - SU011248 is an exciting, new, experimental drug that inhibits a number of proteins, or more specifically receptor tyrosine kinases, in tumor cells. These proteins are active in cellular pathways that are important for development and growth of a variety of different cancers. The t...

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and gallbladder cancers. We are looking to improve treatment results. We will attempt to do so by adding sorafenib (a type of monoclonal antibody) to your treatment plan. Sorafenib acts by attaching to blocking specific targets on cells. These targets may ...


Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

Background: - Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used to help identify damaged liver tissue, can help tell these types of prostate cancer apart. It may be able to identify if a man has a type of prostate cancer for which hormone the...

ACTolog in Patients With Solid Cancers

The ACTolog clinical trial IMA101-101 is a first-in-human trial for the ACTolog concept targeting patients with advanced stage solid cancers depending on the expression of ACTolog targets within their tumors. In the IMA101-101 trial, a patient's tumor is first biomarker tested for the expression of ACTolog targets ("antigen warehouse"). Only if the individual tumor is positive for at least one ACTolog target, the patient will be enrolled in the trial.

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

A two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer.

Depiction of Prostate Cancer Treatment Alternatives in Greece

A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice. - Target Group: Patients with locally advanced or metastatic prostate cancer. - The first 10 consecutive patients records that meet the entry criteria.

Vitamin D Effects on Prostate Pathology

There is much interest in understanding the role that vitamin D3 (cholecalciferol) plays in various cancers, and in the prognosis of various cancers once they are discovered. The purpose of this study is to examine the effects of vitamin D on prostate cancer-associated lesions and on vitamin D metabolites in prostate tissue. We will give vitamin D3 to men when they are scheduled to have their prostate removed because of cancer. The men will take vitamin D at one of 3 doses for ...

Molecular Studies and Clinical Correlations in Human Prostatic Disease

The purpose of this study is to collect tissue samples from normal and cancerous prostates, and blood and urine from men with prostate cancer or prostatic disease. We then store them for use by researchers who study prostate cancer and try to find better ways to prevent it and treat it. We will look for genetic changes in cancer cells and protein markers in these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive ...

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

Prostate cancer is a commonly diagnosed cancer, and is the second leading cause of cancer deaths among men in the U.S. The subgroup of men with advanced prostate cancer is particularly vulnerable to difficult choices for treatment because of the nature of their disease and having limited options. This study will test the use of an innovative Registered Nurse-Community Patient Navigator team delivered interactive mHealth decision aid for patients with advanced prostate cancer to...

The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease

The measurement of circulating tumor cells is pursued in several cancers including breast and prostate cancer. The number of cells measured in these cancers has been shown to be prognostic. There is little information on the presence or importance of circulating tumor cells in bladder cancer. This trial is designed to determine if patients with advanced bladder cancer have circulating tumor cells and if these circulating cells are affected by treatment of the cancer.

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery. Prostate cancer is a common and important health issue facing men in the United States. Most patients with prostate cancer are identified when the disease is limited to the prostate gland itself (localized prostate cancer). A standard treatment for some patients with localized prostate...

Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers

Standard treatment of locally-advanced prostate cancers consists in the association of radiotherapy of prostate and seminal vesicles (SV) and androgen deprivation (AD) for 3 years. This treatment is usually preceded by pelvic lymphadenectomy to assess the possible extension to lymph nodes of prostatic cancer and to avoid irradiating the pelvis in case of no lymph node involvement. However, radiotherapy leads usually to about 30% of grade ≥2 risk of bladder and/or rectal toxic...

Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers

This is a multicenter, cohort study based on medico-administrative data from pathology laboratory registries and drug reimbursement files (CNAM-TS).

Tivozanib + Enzalutamide in Adv Prostate Cancer

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether they work in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied and that research doctors are trying to find out more about it, such as the safest dose to use and the side effects they may cause. It also means that the FDA has not yet approved the combination. The two d...

Development of Diagnostics and Treatment of Urological Cancers

The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation and improve outcome of urologic cancers.

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts. Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will enroll up to 48 patients with advanced solid tumors and hematological cancers. Part B will include monotherapy expansion cohorts in advanced solid and hematologic cancers to further examine SRF231 as monotherapy (100 patients total).

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

Background: Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therapy. These could help manage prostate cancer. Researchers want to study how imaging can provide a profile of prostate cancer. They want to collect data to make diagnosis and treatments better. Objectives: To gather data about the radiological and clinical course of pros...

Effect of Casodex on Tumour Hypoxia - Prostate Cancer

Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.

NY-ESO Phase I Study for Prostate Cancer

Prostate cancer is the most common type of cancer found in American men, other than skin cancer. The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007. About 27,050 men will die of this disease. Prostate cancer is the second leading cause of cancer death in men. Lung cancer is the first. While 1 man in 6 will get prostate cancer during his lifetime, only 1 man in 34 will die of this disease. The death ra...

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

RATIONALE: Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer).

Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer

Many prostate cancer are slow or non progressive forms that would never impair quality or quantity of like of life if undetected. For this localized prostate cancer, the recommendation is an active surveillance, however often experienced by the patient as a lack of care. Thus the introduction of new potent androgen receptor inhibitor raise the question of the benefit of early hormonal therapy in localized prostate cancers. The aim of this study is to assess whether treatment w...

Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers

This study is to Evaluate the response rate and toxicity profile of infusional 5 fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) in 1st line treatment of advanced biliary tract cancers and also To assess progression free survival and overall survival of FOLFIRINOX in first line treatment of advanced biliary tract cancers

Molecular Mechanisms Underlying Prostate Cancer Disparities

The purpose of this study is to further elucidate the molecular mechanisms underlying prostate cancer disparities. In previous work the investigators have identified a set of differentially deregulated genes in African American versus Caucasian American prostate cancer. Based on these findings, they hypothesize that they will be able to validate these targets, originally identified in the previous work conducted at The George Washington University Medical Center, in an indepe...

Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in > 70%, approximately, of all cervical cancers. Recently, Merck's HPV vaccine Gardasil® [quadrivalent human papillomavirus (HPV-6,11,16,18 L1 VLP) recombinant vaccine] has been approved by the FDA for prevention of genital tract cancers and pre-cancers and geni...


More From BioPortfolio on "Treatment targets with advanced prostate cancers"

Quick Search